Pepgen reports inducement grant under nasdaq listing rule 5635(c)(4) to newly appointed senior vice president, clinical development

Boston--(business wire)--pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under pepgen's 2024 inducement plan as a material inducement to employment to its newly appointed senior vice president, clinical development, steve han, md, phd, mmsc. on november 20, 2024, dr. han receive.
PEPG Ratings Summary
PEPG Quant Ranking